Sparse data are available about the natural history of hemoglobin (Hb) level trends in contemporary patients with anemia, chronic kidney disease (CKD), and type 2 diabetes mellitus. Skali, Hicham Lin, Julie Pfeffer, Marc A Chen, Chao-Yin Cooper, Mark E McMurray, John J V Nissenson, Allen R Remuzzi, Giuseppe Rossert, Jerome Parfrey, Patrick S Scott-Douglas, Nairne W Singh, Ajay K Toto, Robert Uno, Hajime Ivanovich, Peter Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm. We evaluated the effects of darbepoetin alfa on clinical outcomes in patients with systolic heart failure and anemia. We evaluated the effects of darbepoetin alfa on clinical outcomes in patients with systolic heart failure and anemia.Patients with systolic heart failure and anemia have worse symptoms, functional capacity, and outcomes than those without anemia. Patients with systolic heart failure and anemia have worse symptoms, functional capacity, and outcomes than those without anemia. Swedberg, Karl Young, James B Anand, Inder S Treatment of anemia with darbepoetin alfa in systolic heart failure The aim of the present analysis was to evaluate the efficacy and tolerability of an every-2-week (Q2W) schedule of darbepoetin alfa. Mann, J Kessler, M Villa, Giulio PalludanĪIM: Darbepoetin alfa has a longer half-life than epoetin-(EPO) alfa or beta, allowing administration at less frequent intervals for the treatment of renal anemia. assigned to darbepoetin alfa and 496 patients assigned to placebo (Pchronic kidney disease.ĭarbepoetin alfa once every 2 weeks for treatment of anemia in dialysis patients METHODS: In this study involving 4038 patients with diabetes, chronic kidney disease, and anemia, we randomly assigned 2012 patients to darbepoetin alfa to achieve a hemoglobin level of approximately 13 g per deciliter and 2026 patients to placebo, with rescue darbepoetin alfa when the hemoglobin. Although darbepoetin alfa can effectively increase hemoglobin levels, its effect on clinical outcomes in these patients has not been adequately. Pfeffer, Marc A Burdmann, Emmanuel A Chen, Chao-YinīACKGROUND: Anemia is associated with an increased risk of cardiovascular and renal events among patients with type 2 diabetes and chronic kidney disease. We sought to identify baseline characteristics and postrandomization factors that might explain this association.Ī trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease More strokes were observed in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) among patients assigned to darbepoetin alfa. Skali, Hicham Parving, Hans-Henrik Parfrey, Patrick S Further informationĪlways consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa Consult with your healthcare professional before taking any medication. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. This means it is still under development and may contain inaccuracies. Important Notice: The international database is in BETA release. Uridine 5'-Triphosphate is reported as an ingredient of Nucleo C.M.P Forte in the following countries: Ingredient matches for Nucleo C.M.P Forte CytidineĬytidine is reported as an ingredient of Nucleo C.M.P Forte in the following countries: Nucleo C.M.P Forte may be available in the countries listed below.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |